City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  82  Clinical trial(s) found  (Page 1 of 4 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 16176

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase I/II, Multicenter, Open-label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients with Previously Treated EGFRmut and Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 16036 ClinicalTrials.gov Number: NCT02535338

Principal Investigator: Karen Reckamp, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-80, NCI#9878: A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-Small Cell Lung Cancer

COH Protocol Number: 16006 ClinicalTrials.gov Number: NCT02453087

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase I/IB Dose Escalation Study Evaluating the Pharmacokinetics, Safety, Tolerability, and Preliminary Efficacy of DCDS0780A, Alone or in Combination with Rituximab, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

COH Protocol Number: 15467 ClinicalTrials.gov Number: NCT01953692

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies

COH Protocol Number: 15429 ClinicalTrials.gov Number: NCT02677922

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects with Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy

COH Protocol Number: 15428 ClinicalTrials.gov Number: NCT02567656

Principal Investigator: Jasmine Zain, MD
Sponsor: Industrial

Title:  A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

COH Protocol Number: 15404 ClinicalTrials.gov Number: NCT02419560

Principal Investigator: Robert Chen, MD
Sponsor: Institutional

Title:  Multi-institution Phase I/Ib Study of Ibrutinib with ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma

COH Protocol Number: 15391 ClinicalTrials.gov Number: NCT02500407

Principal Investigator: L. elizabeth Budde, MD, PhD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

COH Protocol Number: 15358 ClinicalTrials.gov Number: NCT02625480

Principal Investigator: Joseph Rosenthal, MD
Sponsor: Industrial

Title:  A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)

COH Protocol Number: 15340 ClinicalTrials.gov Number: NCT02548962

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Randomized Multicenter Study of Ibrutinib in Combination with Pomalidomide (Pomalyst™) and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 15337 ClinicalTrials.gov Number: NCT02610062

Principal Investigator: Monzr Al malki, MD
Sponsor: Industrial

Title:  A Phase 1 Study Evaluating Safety,Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)

COH Protocol Number: 15335 ClinicalTrials.gov Number: NCT02614560

Principal Investigator: Ibrahim Aldoss, MD
Sponsor: Industrial

Title:  A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence with Allogeneic Hematopoietic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

COH Protocol Number: 15333 ClinicalTrials.gov Number: NCT02632708

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

COH Protocol Number: 15321 ClinicalTrials.gov Number: NCT02663518

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  A Phase 1a/1b Dose Escalation and Expansion Trial of Single-agent TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies

COH Protocol Number: 15318 ClinicalTrials.gov Number: NCT02702141

Principal Investigator: L. elizabeth Budde, MD, PhD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19B in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

COH Protocol Number: 15303 ClinicalTrials.gov Number: NCT02592577

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase I/II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 15275 ClinicalTrials.gov Number: NCT02588612

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 15270 ClinicalTrials.gov Number: NCT02580552

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type

COH Protocol Number: 15256 ClinicalTrials.gov Number: NCT02496208

Principal Investigator: Sumanta Pal, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-81, NCI#9681: A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

COH Protocol Number: 15238 ClinicalTrials.gov Number: NCT02560779

Principal Investigator: Joseph Chao, MD
Sponsor: Industrial

Title:  An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients with Hepatocellular Carcinoma (HCC)

COH Protocol Number: 15236 ClinicalTrials.gov Number: NCT02535312

Principal Investigator: Marianna Koczywas, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-76, NCI#9837: Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed

COH Protocol Number: 15232 ClinicalTrials.gov Number: NCT02513472

Principal Investigator: Yuan Yuan, MD, PhD
Sponsor: Industrial

Title:  An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)

COH Protocol Number: 15219 ClinicalTrials.gov Number: NCT02383212

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A First-in-Human Study of Repeat Dosing with REGN2810, A Monoclonal, Fully Human Antibody to Programmed Death-1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

COH Protocol Number: 15213 ClinicalTrials.gov Number: NCT02453620

Principal Investigator: George Somlo, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-83, NCI#9844: A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors

COH Protocol Number: 15209 ClinicalTrials.gov Number: NCT02631044

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.